Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Molecular Pathology

• Publication date

  2003-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1136/MP.56.3.137PMID 12782759PMCID PMC1187308
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Molecular changes in the Ki‐ras and APC genes in colorectal adenomas and carcinomas arising in the same patient

  2001cited by this paper
• Involvement of chemokine receptors in breast cancer metastasis

  2001cited by this paper
• Comparative genomic hybridization analysis of primary colorectal carcinomas and their synchronous metastases

  1999cited by this paper
• K‐ras mutation and loss of heterozygosity of the adenomatous polyposis coli gene in patients with colorectal adenomas with in situ carcinoma

  1999cited by this paper
• Comparison of losses of heterozygosity and replication errors in primary colorectal carcinomas and corresponding liver metastases

  1999cited by this paper
• Heterogeneity of mutant versus wild‐type Ki‐ras in primary and metastatic colorectal carcinomas, and association of codon‐12 valine with early mortality

  1998cited by this paper
• Analysis of colorectal cancer by comparative genomic hybridization: evidence for induction of the metastatic phenotype by loss of tumor suppressor genes.

  1998cited by this paper
• Ki‐ras mutations in adenomas from cancer‐bearing and cancer‐freee bowel

  1998cited by this paper
• Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K‐ras‐2 mutation type

  1993cited by this paper
• Stability of K-ras mutations throughout the natural history of human colorectal cancer.

  1992cited by this paper
• A CA repeat 30-70 KB downstream from the adenomatous polyposis coli (APC) gene.

  1991cited by this paper
• A genetic model for colorectal tumorigenesis.

  1990cited by this paper

• The impact of RAS mutation on the treatment strategy of colorectal cancer

  2023cites this paper
• Report of two patients in whom comparisons of the somatic mutation profile were useful for the diagnosis of metastatic tumors

  2022cites this paper
• The role of KRAS and NRAS mutation detection in determining the therapy strategy for colorectal cancer

  2022cites this paper
• Colorectal cancers with a residual adenoma component: Clinicopathologic features and KRAS mutation

  2022cites this paper
• Discordance of KRAS Mutational Status between Primary Tumors and Liver Metastases in Colorectal Cancer: Impact on Long-Term Survival Following Radical Resection

  2021cites this paper
• Biomarker concordance between primary colorectal cancer and its metastases

  2019cites this paper
• Pathways of dissemination in colorectal cancer

  2018influential citation
• Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, Third Edition

  2018cites this paper
• Spatio-temporal tumor heterogeneity in metastatic CRC tumors: a mutational-based approach

  2018cites this paper
• Benefit of rebiopsy for deciding treatment strategy in rectal cancer: A case report.

  2017cites this paper
• BRAF Mutation Status Concordance Between Primary Cutaneous Melanomas and Corresponding Metastases: A Review of the Latest Evidence

  2017cites this paper
• Concordancia mutacional de BRAF entre melanoma primario cutáneo y sus correspondientes metástasis. Revisión de la evidencia actual

  2017cites this paper
• BRAF Mutation Status Concordance Between Primary Cutaneous Melanomas and Corresponding Metastases: A Review of the Latest Evidence.

  2017cites this paper
• ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

  2016cites this paper
• Tumour heterogeneity: principles and practical consequences

  2016cites this paper
• KRAS discordance between primary and recurrent tumors after radical resection of colorectal cancers

  2015cites this paper
• KRAS, NRAS, BRAF mutation comparison of endoscopic and surgically removed primary CRC paired samples: is endoscopy biopsy material adequate for molecular evaluation?

  2015influential citation
• Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases

  2015cites this paper
• Pragmatic issues in biomarker evaluation for targeted therapies in cancer

  2015cites this paper
• Molecular Alterations and Biomarkers in Colorectal Cancer

  2014cites this paper
• Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer.

  2014cites this paper
• Contributions of molecular analysis to the diagnosis and treatment of gastrointestinal neoplasms.

  2013cites this paper
• KRAS testing in metastatic colorectal carcinoma: challenges, controversies, breakthroughs and beyond

  2013cites this paper
• Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis

  2013cites this paper
• TGF-β in Cancer Stem Cells

  2013cites this paper
• Studies in colorectal cancer metastases: implications for clinical practice

  2013influential citation
• Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease

  2012cites this paper
• KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer

  2012cites this paper
• Concordant KRAS Mutations in Primary and Metastatic Colorectal Cancer Tissue Specimens: A Meta-Analysis and Systematic Review

  2012cites this paper
• Predictive and Prognostic Factors in Colorectal Cancer: A Personalized Approach

  2011cites this paper
• Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapy

  2011cites this paper
• Kolorektal kanser: Genetik ve moleküler biyoloji araştirmalari hasta tedavisine yeterince yansiyor mu? Colorectal cancer: are genetic and molecular biology researches reflected enough in the patient management?

  2011cites this paper
• The role of kras mutations and MSI status in diagnosis of colorectal cancer

  2011cites this paper
• Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review.

  2011cites this paper
• Predictive and Prognostic Markers in Colorectal Cancer

  2011cites this paper
• Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping.

  2011cites this paper
• KRAS Mutation Is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer

  2011cites this paper
• Morphological and molecular heterogeneity in colorectal neoplasms with K-RAS mutation. A report of two cases.

  2011cites this paper
• Estudio de las metástasis hepáticas de cáncer colorrectal con rescate quirúrgico en un hospital de tercer nivel: identificación de marcadores biológicos pronósticos

  2011cites this paper
• KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients

  2011cites this paper
• Molecular Testing in Colorectal Carcinoma.

  2010cites this paper
• Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases

  2010cites this paper
• Cancer stem cell and niche.

  2010cites this paper
• Colorectal cancer molecular biology moves into clinical practice

  2010cites this paper
• Accurate KRAS mutation testing for EGFR-targeted therapy in colorectal cancer: emphasis on the key role and responsibility of pathologists.

  2010cites this paper
• Kras in metastatic colorectal cancer.

  2010cites this paper
• KRAS Mutation Testing in Colorectal Cancer

  2009cites this paper
• Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer

  2009cites this paper
• Therapeutic implications of cancer initiating cells

  2009cites this paper
• KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue.

  2009cites this paper
• High Epidermal Growth Factor Receptor Expression in Metastatic Colorectal Cancer Lymph Nodes May Be More Prognostic of Poor Survival Than in Primary Tumor

  2009cites this paper
• KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue

  2009cites this paper
• K-Ras Mutations and Treatment Outcome in Colorectal Cancer Patients Receiving Exclusive Fluoropyrimidine Therapy

  2008cites this paper
• cinewillbeachievedwhentechnicaladvances,newskills,adequate financialresources,effectivepolicychanges,andsocial,emotional, psychological, and spiritual support for patients and their caregiv- ers that support the dignity of both are fully integrated. Achieving this goal requires balancing clinical ar

  2008cites this paper
• [Prognosis factors in colorectal cancer].

  2008cites this paper
• Is the cancer stem cell population "a player" in multi-drug resistance?

  2008cites this paper
• K-RasMutations and Treatment Outcome in Colorectal Cancer Patients Receiving Exclusive FluoropyrimidineTherapy

  2008cites this paper
• Cancer stem cells: models and concepts.

  2007cites this paper
• Phenotypic characterization of human colorectal cancer stem cells

  2007cites this paper
• Diet, lifestyle, heritable factors and colorectal carcinogenesis: associations with histopathological and molecular endpoints

  2007cites this paper
• Diet, lifestyle and risk of K‐ras mutation‐positive and ‐negative colorectal adenomas

  2006cites this paper
• Epigenetic profiling of synchronous colorectal neoplasias by quantitative DNA methylation analysis

  2006cites this paper
• Hypermethylation of the TPEF/HPP1 gene in primary and metastatic colorectal cancers.

  2005cites this paper
• Molecular analysis of APC promoter methylation and protein expression in colorectal cancer metastasis.

  2005cites this paper